Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Learn more about:
Related Clinical Trial
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Patient Reported Outcome Measures (PROMs) With Trabectedin
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma